These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18563471)

  • 1. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder.
    Arabgol F; Panaghi L; Hebrani P
    Eur Child Adolesc Psychiatry; 2009 Jan; 18(1):53-9. PubMed ID: 18563471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Ratner S; Laor N; Bronstein Y; Weizman A; Toren P
    J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):428-33. PubMed ID: 15843764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of theophylline compared to methylphenidate for the treatment of attention-deficit hyperactivity disorder in children and adolescents: a pilot double-blind randomized trial.
    Mohammadi MR; Kashani L; Akhondzadeh S; Izadian ES; Ohadinia S
    J Clin Pharm Ther; 2004 Apr; 29(2):139-44. PubMed ID: 15068402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial.
    Golubchik P; Sever J; Weizman A
    Clin Neuropharmacol; 2013; 36(2):37-41. PubMed ID: 23503544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder.
    Tehrani-Doost M; Moallemi S; Shahrivar Z
    J Child Adolesc Psychopharmacol; 2008 Apr; 18(2):179-84. PubMed ID: 18439114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
    Lin DY; Kratochvil CJ; Xu W; Jin L; D'Souza DN; Kielbasa W; Allen AJ
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):190-200. PubMed ID: 24840045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Ghajar A; Aghajan-Nashtaei F; Afarideh M; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):331-338. PubMed ID: 29469593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crocus sativus L. Versus Methylphenidate in Treatment of Children with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Pilot Study.
    Baziar S; Aqamolaei A; Khadem E; Mortazavi SH; Naderi S; Sahebolzamani E; Mortezaei A; Jalilevand S; Mohammadi MR; Shahmirzadi M; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):205-212. PubMed ID: 30741567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.
    Quintero J; López-Muñoz F; Alamo C; Loro M; García-Campos N
    Atten Defic Hyperact Disord; 2010 Nov; 2(3):107-13. PubMed ID: 21432596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double-blind and randomized trial.
    Davari-Ashtiani R; Shahrbabaki ME; Razjouyan K; Amini H; Mazhabdar H
    Child Psychiatry Hum Dev; 2010 Dec; 41(6):641-8. PubMed ID: 20517641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agomelatine as a Treatment for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Double-Blind, Randomized Clinical Trial.
    Salardini E; Zeinoddini A; Kohi A; Mohammadi MR; Mohammadinejad P; Khiabany M; Shahriari M; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):513-9. PubMed ID: 27286139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.